IMMUNOVANT INC IMVT 深 沪
已收盘 08-15 16:00:00 美东时间
15.22
+0.020
+0.13%
华盛通- 最 高15.31
- 今 开15.31
- 成交量 178.14万股
- 最 低 14.98
- 昨 收 15.20
- 总市值 26.03亿
- 52周最高 34.47
- 市盈率 静 --
- 换手率 1.04%
- 52周最低 12.72
- 委 比 -58.03%
- 总股本 1.71亿
- 历史最高 53.75
- 量 比 1.53
- 振 幅 2.17%
- 历史最低 3.145
- 每 手 1
- 风险率 4.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $37
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $40 to $37.
08-12 23:44
Immunovant GAAP EPS of -$0.71
Immunovant press release (NASDAQ:IMVT): Q1 GAAP EPS of -$0.71 misses by $0.02. As of June 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $598.9 million, providing runway for an...
08-11 19:21
Immunovant Q1 EPS $(0.71), Inline
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 18.33 percent decrease over losses of $(0.60) per share from the same period last year.
08-11 19:13
A Glimpse of Roivant Sciences's Earnings Potential
Roivant Sciences (NASDAQ:ROIV) is preparing to release its quarterly earnings o...
08-08 22:05
UBS Maintains Neutral on Immunovant, Raises Price Target to $18
UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $17 to $18.
07-29 06:18
Roivant Sciences sets $500M stock repurchase program
Roivant Sciences (NASDAQ:ROIV) has set a stock repurchase program to buy back up to $500M of its common shares. The program will be funded with available cash and cash equivalents on hand and does not...
06-25 19:51
Immunovant shares are trading higher following a Q4 EPS beat.
Immunovant shares are trading higher following a Q4 EPS beat.
05-30 02:02
Immunovant Q4 EPS $(0.64) Beats $(0.73) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.73) by 12.33 percent. This is a 23.08 percent decrease over losses of $(0.52) per share from the
05-29 19:09
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant Inc. reported updates on its IMVT-1402 program, including plans for potentially registrational studies in Graves’ disease (GD) and Sjögren’s disease (SjD) starting in summer 2025. Positive data from batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) showed correlation between IgG reductions and clinical improvements. The company has $714 million in cash, providing runway through GD ...
05-29 11:00
Roivant Sciences's Earnings Outlook
Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Th...
05-28 23:02
